

• **Name:** Patrick TAN

• **Current Position:**

Professor, Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School
Deputy Executive Director, Biomedical Research Council, A*STAR
Director, SingHealth Duke-NUS Institute of Precision Medicine (PRISM)

• **Country:** Singapore

• **Educational Background:**

1986 - 1987 National Junior College, Singapore, GCE 'A' Level
1988 - 1992 Harvard University, B.A. (Biochemistry)
1992 - 2000 Stanford University School of Medicine, M.D., Ph.D
(Developmental Biology)

• **Professional Experience:**

2014 - 2016 Associate Director (Genomic Medicine), Genome Institute of Singapore
2013 - 2016 Senior Group Leader, Genome Institute of Singapore
2009 - 2014 Research Associate Professor, Duke University, USA
2004 - 2013 Senior Research Fellow (Adjunct), Defence Medical and Environmental Research Institute, Defence Science Organization (DMERI@DSO), Singapore
2003 - 2012 Associate Professor (Adjunct), Dept of Physiology, NUS
2008 - 2012 Program Leader, Genomic Oncology, Cancer Science Institute of Singapore
2004 - 2013 Group Leader, Genome Institute of Singapore
2006 - 2012 Associate Professor (Awarded Tenure in 2009), Cancer and Stem Cell Biology, Duke-NUS Medical School Singapore
2005 - 2008 Associate Professor (Adjunct), School of Computer Science, Nanyang Technological University, Singapore
2002 - 2007 Chief Scientific Officer, Agenica Research Pte Ltd (Joint Venture with NCCS, Mitsui Corp, and Shimadzu Corp)
2002 - 2006 Principal Investigator, National Cancer Centre, Singapore
2003 - 2004 Senior Research Fellow, Defence Medical and Environmental Research Institute (DMERI@DSO), Singapore
2004 Visiting Scientist, Broad Institute, Cambridge, MA
2000 - 2003 Research Scientist, Defence Medical Research Institute, Singapore

• **Professional Organizations:**

Member, American Society for Clinical Investigation (ASCI)
Member, Academy of Medicine Singapore
Member, International Gastric Cancer Association

• **Main Scientific Publications:**

(Selected from over 200 publications)

- Weng Khong Lim et al (2018). Beyond fitness tracking: The use of consumergrade wearable data from normal volunteers in cardiovascular and lipidomics research. *PLoS Biol.* Feb; 16(2)
- Raghav Sundar and PATRICK TAN (2018) Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards? *Cancer Discov.* Jan; 8(1):14-16.
- Huang KK et al. (2018) Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer. *Cancer Cell.* 33(1):137-150.
- Yao X et al. (2017) VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. *Cancer Discov.* 7(11):1284-1305.
- Jusakul A et al. (2017) Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discov.* 7(10):1116-1135.
- Qamra A et al (2017) Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. *Cancer Discov.* (6):630-651.
- Tan J et al. (2015) Genomic landscapes of breast fibroepithelial tumors. *Nat Genet.* 2015 Nov; 47(11):1341-5.
- Lim WK et al. (2014) Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. *Nat Genet.* 46(8):877-80.
- Chan-On W et al. (2013) *Nat Genet.* 45(12):1474-8.
- Poon SL et al (2013) Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. *Sci Transl Med.* 5(197):197ra101.
- Zang ZJ et al. (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. *Nat Genet.* 44(5):570-4.